Stop Vaping Ads Act of 2019

Bill: 116-hr-4249
Sponsor: full_name: Rep. Brownley, Julia [D-CA-26]
Introduced: 2019-09-09
Policy area: Health
Subjects: Drug, alcohol, tobacco use

Marketing and advertising
Latest action: action_date: 2019-09-18
text: Sponsor introductory remarks on measure. (CR H7760)

Summaries:
action_date: 2019-09-09
action_desc: Introduced in House
text: <p><b>Stop Vaping Ads Act of 2019 </b></p> <p>This bill generally prohibits electronic advertisements of electronic nicotine delivery systems (e.g., e-cigarettes or vape pens).</p>

tv_txt: I 116th CONGRESS 1st Session H. R. 4249 IN THE HOUSE OF REPRESENTATIVES September 9, 2019 Ms. Brownley of California introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Cigarette Labeling and Advertising Act to extend the prohibition on electronic advertisements of cigarettes and little cigars to electronic nicotine delivery systems.

1. Short title This Act may be cited as the Stop Vaping Ads Act of 2019 . 2. Prohibition on electronic advertisements of electronic nicotine delivery systems Section 6 of the Federal Cigarette Labeling and Advertising Act ( 15 U.S.C. 1335 ) is amended— (1) by striking and little cigars and inserting , little cigars, and electronic nicotine delivery systems ; (2) by striking After and inserting the following: (a) In general After ; and (3) by adding at the end the following: (b) Electronic nicotine delivery system defined In this section, the term electronic nicotine delivery system — (1) means any electronic device that delivers nicotine, flavor, or another substance via an aerosolized solution to the user inhaling from the device (including e-cigarettes, e-hookah, e-cigars, vape pens, advanced refillable personal vaporizers, and electronic pipes) and any component, liquid, part, or accessory of such a device, whether or not sold separately; and (2) does not include a product that— (A) is approved by the Food and Drug Administration for sale as a tobacco cessation product or for another therapeutic purpose; and (B) is marketed and sold solely for a purpose described in subparagraph (A). .